InMed Pharmaceuticals (INM) Income from Continuing Operations (2021 - 2026)

InMed Pharmaceuticals has reported Income from Continuing Operations for 6 years, with the latest figure at 2791751.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Continuing Operations fell 35.06% year-over-year to 2791751.0; the trailing twelve-month figure through Mar 2026 stood at 7853314.0 (up 4.81% YoY), and the FY2025 full-year result was 8162133.0, down 6.34% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 2791751.0, down from 2028223.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 336591.0 in Q2 2023, with the low at 7870023.0 in Q2 2022.
• Historically, Income from Continuing Operations has averaged 2419337.35 across 5 years, with a median of 2028223.0 in 2025.
• Annual changes were most pronounced in 2023 — Income from Continuing Operations jumped 95.72% — and 2024, when it tumbled 473.57%.
• InMed Pharmaceuticals' Income from Continuing Operations stood at 2098087.0 in 2022, then advanced by 29.55% to 1478185.0 in 2023, then slumped by 74.2% to 2575024.0 in 2024, then advanced by 21.23% to 2028223.0 in 2025, then plunged by 37.65% to 2791751.0 in 2026.
• The last three Income from Continuing Operations figures came in at 2791751.0 (Q1 2026), 2028223.0 (Q4 2025), and 1726899.0 (Q3 2025), per Business Quant data.